Do I need to re-test patients at relapse who had an IDH mutation at diagnosis?

Published on May 2, 2018 in Diagnosis

Download Transcript Download Audio

Hetty E. Carraway, MD
Staff Physician
Hematologic Oncology and Blood Disorders
Taussig Cancer Institute, Cleveland Clinic
Cleveland, Ohio

Welcome to Managing AML, I am Dr. Hetty Carraway. Today, I would like to discuss whether I re-test patients at relapse who were found to have an IDH mutation at diagnosis. I believe that, for many of our patients that do relapse with their AML, it is probably important for us to have a better understanding of clonal evolution, and it is reasonable to re-test patients to see if their IDH mutation is still present at relapse. For this reason, I would favor re-testing patients at the time of relapse to clarify whether or not the IDH mutation is still present, and to ensure that if we were to proceed with enasidenib as a single agent in that setting, that it would actually be a lesion that is present on the leukemia at that time. Thank you for viewing this activity.

Last modified: May 1, 2018